Limits...
Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies.

Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J - PLoS ONE (2016)

Bottom Line: However, the results of the studies are conflicting.In addition, a similar result was also found in T vs.Additional epidemiological studies are needed to confirm our findings.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Zhongshan Affiliated Hospital of Sun Yat-sen University, Zhongshan, Guangdong 528403, China.

ABSTRACT
Programmed cell death-1 (PD-1) plays an important inhibitory role in anti-tumor responses, so it is considered as a powerful candidate gene for individual's genetic susceptibility to cancer. Recently, some epidemiological studies have evaluated the association between PD-1 polymorphisms and cancer risk. However, the results of the studies are conflicting. Therefore, a meta-analysis was performed. We identified all studies reporting the relationship between PD-1 polymorphisms and cancers by electronically searches. According to the inclusion criteria and the quality assessment of Newcastle-Ottawa Scale (NOS), only high quality studies were included. A total of twelve relevant studies involving 5,206 cases and 5,174 controls were recruited. For PD-1.5 (rs2227981) polymorphism, significantly decreased cancer risks were obtained among overall population, Asians subgroup and population-based subgroup both in TT vs. CC and TT vs. CT+CC genetic models. In addition, a similar result was also found in T vs. C allele for overall population. However, there were no significant associations between either PD-1.9 (rs2227982) or PD-1 rs7421861 polymorphisms and cancer risks in all genetic models and alleles. For PD-1.3 (rs11568821) polymorphism, we found different cancer susceptibilities between GA vs. GG and AA vs. AG+GG genetic models, and no associations between AA vs. GG, AA+AG vs. GG genetic models or A vs. G allele and cancer risks. In general, our results firstly indicated that PD-1.5 (rs2227981) polymorphism is associated a strongly decreased risk of cancers. Additional epidemiological studies are needed to confirm our findings.

Show MeSH

Related in: MedlinePlus

Forest plots of the PD-1 rs7421861 polymorphism and cancer risk for overall populations (A for CC vs. TT; B for CC vs. CT+TT; C for CC+CT vs. TT; D for CT vs. TT and E for C vs. T).The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4816386&req=5

pone.0152448.g006: Forest plots of the PD-1 rs7421861 polymorphism and cancer risk for overall populations (A for CC vs. TT; B for CC vs. CT+TT; C for CC+CT vs. TT; D for CT vs. TT and E for C vs. T).The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.

Mentions: The PD-1.9 (rs2227982) and PD-1 rs7421861 polymorphisms were both discussed in four studies, which including 1,961 and 1,975 cases, and 2,390 and 2,403 controls, respectively. Overall, there were no significant associations between either PD-1.9 (rs2227982) (Fig 5) or PD-1 rs7421861 (Fig 6) and cancers in all genetic models and allele (PD-1.9: TT vs. CC: OR = 1.10, 95% CIs: 0.84–1.45, P = 0.487, I2 = 52.4%; TT vs. CT+CC: OR = 1.04, 95% CIs: 0.89–1.21, P = 0.609, I2 = 15.5%; TT+CT vs. CC: OR = 1.06, 95% CIs: 0.93–1.22, P = 0.399, I2 = 41.6%; TC vs. CC: OR = 1.04, 95% CIs: 0.90–1.20, P = 0.595, I2 = 25.8%; T vs. C: OR = 1.04, 95% CIs: 0.95–1.14, P = 0.393, I2 = 41.5%; PD-1 rs7421861: CC vs. TT: OR = 0.86, 95% CIs: 0.61–1.23, P = 0.419, I2 = 0.0%; CC vs. CT+TT: OR = 0.84, 95% CIs: 0.59–1.19, P = 0.331, I2 = 0.0%; CC+CT vs. TT: OR = 1.10, 95% CIs: 0.97–1.24, P = 0.137, I2 = 0.0%; CT vs. TT: OR = 1.13, 95% CIs: 0.99–1.28, P = 0.072, I2 = 0.0%; C vs. T: OR = 1.06, 95% CIs: 0.95–1.18, P = 0.322, I2 = 0.0%). All the studies about these two polymorphisms are conducted in Asians. When concerning the control sources, there are two hospital-based and two population-based articles studied about the PD-1.9 (rs2227982) polymorphism, while three hospital-based and one population-based article studied about the PD-1 rs7421861 polymorphism.


Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies.

Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J - PLoS ONE (2016)

Forest plots of the PD-1 rs7421861 polymorphism and cancer risk for overall populations (A for CC vs. TT; B for CC vs. CT+TT; C for CC+CT vs. TT; D for CT vs. TT and E for C vs. T).The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4816386&req=5

pone.0152448.g006: Forest plots of the PD-1 rs7421861 polymorphism and cancer risk for overall populations (A for CC vs. TT; B for CC vs. CT+TT; C for CC+CT vs. TT; D for CT vs. TT and E for C vs. T).The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.
Mentions: The PD-1.9 (rs2227982) and PD-1 rs7421861 polymorphisms were both discussed in four studies, which including 1,961 and 1,975 cases, and 2,390 and 2,403 controls, respectively. Overall, there were no significant associations between either PD-1.9 (rs2227982) (Fig 5) or PD-1 rs7421861 (Fig 6) and cancers in all genetic models and allele (PD-1.9: TT vs. CC: OR = 1.10, 95% CIs: 0.84–1.45, P = 0.487, I2 = 52.4%; TT vs. CT+CC: OR = 1.04, 95% CIs: 0.89–1.21, P = 0.609, I2 = 15.5%; TT+CT vs. CC: OR = 1.06, 95% CIs: 0.93–1.22, P = 0.399, I2 = 41.6%; TC vs. CC: OR = 1.04, 95% CIs: 0.90–1.20, P = 0.595, I2 = 25.8%; T vs. C: OR = 1.04, 95% CIs: 0.95–1.14, P = 0.393, I2 = 41.5%; PD-1 rs7421861: CC vs. TT: OR = 0.86, 95% CIs: 0.61–1.23, P = 0.419, I2 = 0.0%; CC vs. CT+TT: OR = 0.84, 95% CIs: 0.59–1.19, P = 0.331, I2 = 0.0%; CC+CT vs. TT: OR = 1.10, 95% CIs: 0.97–1.24, P = 0.137, I2 = 0.0%; CT vs. TT: OR = 1.13, 95% CIs: 0.99–1.28, P = 0.072, I2 = 0.0%; C vs. T: OR = 1.06, 95% CIs: 0.95–1.18, P = 0.322, I2 = 0.0%). All the studies about these two polymorphisms are conducted in Asians. When concerning the control sources, there are two hospital-based and two population-based articles studied about the PD-1.9 (rs2227982) polymorphism, while three hospital-based and one population-based article studied about the PD-1 rs7421861 polymorphism.

Bottom Line: However, the results of the studies are conflicting.In addition, a similar result was also found in T vs.Additional epidemiological studies are needed to confirm our findings.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Zhongshan Affiliated Hospital of Sun Yat-sen University, Zhongshan, Guangdong 528403, China.

ABSTRACT
Programmed cell death-1 (PD-1) plays an important inhibitory role in anti-tumor responses, so it is considered as a powerful candidate gene for individual's genetic susceptibility to cancer. Recently, some epidemiological studies have evaluated the association between PD-1 polymorphisms and cancer risk. However, the results of the studies are conflicting. Therefore, a meta-analysis was performed. We identified all studies reporting the relationship between PD-1 polymorphisms and cancers by electronically searches. According to the inclusion criteria and the quality assessment of Newcastle-Ottawa Scale (NOS), only high quality studies were included. A total of twelve relevant studies involving 5,206 cases and 5,174 controls were recruited. For PD-1.5 (rs2227981) polymorphism, significantly decreased cancer risks were obtained among overall population, Asians subgroup and population-based subgroup both in TT vs. CC and TT vs. CT+CC genetic models. In addition, a similar result was also found in T vs. C allele for overall population. However, there were no significant associations between either PD-1.9 (rs2227982) or PD-1 rs7421861 polymorphisms and cancer risks in all genetic models and alleles. For PD-1.3 (rs11568821) polymorphism, we found different cancer susceptibilities between GA vs. GG and AA vs. AG+GG genetic models, and no associations between AA vs. GG, AA+AG vs. GG genetic models or A vs. G allele and cancer risks. In general, our results firstly indicated that PD-1.5 (rs2227981) polymorphism is associated a strongly decreased risk of cancers. Additional epidemiological studies are needed to confirm our findings.

Show MeSH
Related in: MedlinePlus